This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Program

Times are in Eastern Daylight Time (EDT)

Friday, May 13, 2022

  • 07:15 08:00

    CanHepC Breakfast

  • 08:00 08:15

    Welcome & Introduction

    8:00-8:10: Nadine Kronfli, McGill University, Canada & Rodney Russell, Memorial University, Canada

    8:10-8:15: Opening Prayer, Gayle Pruden, Knowledge Holder and Two-Spirit Dancer (MB)
  • 08:15 09:45

    CanHepC Session 1

    Biomedical Research – Beyond the Scar: Lasting Effects of HCV

    Learning objectives:

    • Learn how the extrahepatic manifestations of HCV is impacted by antiviral therapy
    • Review current literature on extrahepatic HCV persistence and clinical implications

    Co-Chairs: Mohamed Abdel Hakeem, Emory University, USA & Joyce Wilson, University of Sakatchewan, Canada CanHepC trainees introducing plenary speakers: Marylin Rheault and Mohamed Abdelnabi

    8:15-8:30: T Cell Exhaustion in Chronic HCV Infection: Metabolic Regulation, Subsets and Scars, Bertram Bengsch, University of Freiburg, Germany

    8:35-8:55: Hepatitis C: Far From Home... Facts and Controversies of Extrahepatic HCV, Carla Coffin, University of Calgary, Canada

    8:55-9:15: Questions/Panel Discussion

    9:15-9:30: Dissecting the Roles of MIR-122 in the HCV Life Cycle, Marylin Rheault, McGill University, Canada

    9:30-9:45: Pyroptosis Next Door: Understanding the Role of Hepatitis C Virus-Induced Bystander Pyroptosis, Hannah Wallace, Memorial University, Canada

  • 08:30 10:15

    CanNASH Session 1

    Epidemiology and Natural History

    Learning objectives:

    • Summarize the process of identifying patients with NASH at risk for adverse clinical outcomes
    • Restate the key factors that impact survival and clinical outcomes in NASH
    • Describe interventions that may improve survival and reduce clinical outcomes in NASH
    • Summarize recent data regarding mortality risk in NAFLD and NASH
    • Explain new evidence regarding the risk of hepatic and extrahepatic outcomes in NAFLD

    Co-Moderators: Alnoor Ramji, University of British Columbia, Canada & Jonathan Gabor, Health Plus Medical Centre, Canada

    8:30-8:50: Mortality and Clinical Outcomes in NASH, Mary Rinella, University of Chicago, USA

    8:50-9:10: Global Epidemiology of NASH, Tracey Simons, Massachussets General Hospital, USA

    9:10-9:30: Metabolic Key Factors Driving Natural History, Priya Manjoo, University of British Columbia, Canada

    9:30-9:50: Metabolic Associated Fatty Liver Disease is Highly Prevalent in the Post-Acute COVID Syndrome, Jovana Milic, University of Modena and Reggio Emilia, Italy

    9:50-10:15: Q&A

  • 09:45 10:00

    CanHepC: AM BREAK, EXHIBITS & POSTERS

  • 10:00 11:30

    CanHepC Session 2

    Population Health Research – Rising to the Challenge for Priority Populations

    Learning objectives:

    • Review key measures that can be taken to reach Hepatitis C elimination: it is is possible but it wont happen by chance
    • Describe a simple option for treatment and care that is effective for many groups
    • Summarize which groups are disproportionately impacted by HCV in Canada
    • Describe remaining challenges and barriers to HCV elimination in priority populations in Canada
    • Explain the need for specific strategies to address HCV in priority populations, with an important focus on inclusion of affected populations in program design and implementation

    Co-Chairs: Alexandra King, University of Saskatchewan, Canada & Guillaume Fontaine, The Ottawa Hospital Research Institute, Canada

    CanHepC trainees introducing plenary speakers: Manolya Sag and Hannah Wallace

    10:00-10:20: Hepatitis C Treatment in Priority Populations - When Less Is More, Margaret Hellard, Burnet Institute, Australia

    10:20-10:40: No One Left Behind: Ensuring Equity in the Response to HCV Elimination in Canada, Jordan Feld, University Health Network / Toronto General Hospital, Canada

    10:40-11:00: Questions/Panel Discussion

    11:00-11:15: Evidence to Inform the Elimination of Hepatitis C: Mapping the Cascade of Care for First Nations in Ontario, Andrew Bryan Mendlowitz, University Health Network, Canada

    11:15-11:30: Pathways to Hepatitis C/STBBI Testing and Linkage to Care in Correctional Settings: Partnering with People with Lived/Living Experience of Incarceration and Healthcare Providers to Co-Create Policies and Guidelines, Sofia Bartlett, British Columbia Centre for Disease Control, Canada

  • 10:15 10:30

    CanNASH: AM Break, Exhibits & Posters

  • 10:30 12:15

    CanNASH Session 2

    Diagnostics

    Learning objectives:

    • Review the diagnostic tools for NAFLD
    • Examine the use non-invasive tests for NAFLD diagnostic
    • Review how to risk stratify patients at risk of NAFLD in primary care
    • Discuss how to design and implement referral pathways for patients with NAFLD
    • Strategize for diagnosing patients with NAFLD in a cost-effective manner
    • Identify which populations should be targeted for the diagnosis of NAFLD

    Co-Moderators: Giada Sebastiani, McGill University, Canada & Abdel-Aziz Sheheen, University of Calgary, Canada

    10:30-10:50: Guidelines on NAFLD Diagnostics, Laurent Castera, University of Paris, Department of Hepatology, Hopital Beaujon, AP-HP, Clichy, France

    10:50-11:10: Clinical Pathways for NAFLD, Emmanuel Tsochatzis, UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, UK

    11:10-11:30: Cost-Effectiveness of Diagnosing NAFLD, Stephen Congly, University of Alberta, Canada

    11:30-11:50: Screening Patterns and Identification of Non-Alcoholic Fatty Liver Disease in Obese Children in Canadian Primary Care: A Cross Sectional Study, Rachael Morkem, Queen's University, Canada

    11:50-12:15: Q&A

  • 11:30 12:30

    CanHepC Panel Discussion

    Moderator: Renee Masching, Communities, Alliances and Networks (CAAN), Canada

    Approaching research in a good way - From principle to practice – unpacking the meaningful engagement of Indigenous communities and individuals with lived experience in research

    Gayle Pruden, Knowledge Holder and Two-Spirit Dancer (MB)

    Carrielynn Lund, DRUM & SASH Coordinator, CAAN (AL)

    Alexandra King (Nipissing First Nation) Cameco Chair of Indigenous Health and Wellness at the University of Saskatchewan (SK)

    Janet Jull, Faculty of Health Sciences, Queens University (ON)

    Catherine Worthington, Director / Professor, School of Public Health and Social Policy, University of Victoria (BC)
  • 12:15 13:00

    CanNASH Industry Lunch Symposium

    For more information, please visit the "Industry Supported Educational Sessions" webpage.

  • 12:30 14:00

    CanHepC: LUNCH, Exhibits & Posters

    13:00-13:45: CanHepC Poster Evaluation
  • 13:00 13:30

    CanNASH Exhibits & Posters

  • 13:30 15:15

    CanNASH Session 3

    Public Health and Policy

    Learning objectives:

    • Summarize how important it is for a patient to have a community around them
    • Reiterate how transplant affects more than just the patient

    Co-Moderators: Mark Swain, University of Calgary, Canada & Michael Betel, Fatty Liver Alliance, Canada

    13:30-13:50: Patient Perspective, Heather Watson, Citadel Theatre, Canada 

    13:50-14:10: Call to Action on NAFLD from the EASL International Liver Foundation, Jeffrey Lazarus, Barcelona Institute for Global Health (ISGlobal), Spain

    14:10-14:30: A Canadian perspective from the Canadian NASH Network, Giada Sebastiani, McGill University, Canada 

    14:30-14:50: Cause-Specific Mortality in Patient with Cirrhosis: a Population-based Cohort, Peter Wang, Queen's University, Canada 

    14:50-15:15: Q&A

  • 14:00 15:30

    CanHepC Session 3

    Clinical Research – Treatment Simplification: Art or Science?

    Learning objectives:

    • Review simple algorithms for primary care and nurse-led management of Hepatitis C
    • Explain the value of prison-based hepatitis C programs for promoting Hepatitis C elimination
    • Summarize the importance of testing for and managing common concurrent blood-borne and sexually-transmitted infections in persons living with HCV, such as HIV, Hepatitis B, syphilis, chlamydia, and gonorrhea
    • Review a simplified approach to discussing addictions-related concerns for persons living with HCV, and the importance of engaging persons in addictions care and harm reduction to minimize the potential for HCV re-infection after DAA therapy
    • Explain how to decrease barriers to HCV care for priority populations
    • Summarize key tactics in a practical approach to HCV care in corrections

    Co-Chairs: Gisela Macphail, CUPS Liver Clinic, Canada & Curtis Cooper, University of Ottawa, Canada

    CanHepC trainees introducing plenary speakers: Zoe Greenwald and Michael Palmer

    14:00-14:20: Treatment of HCV is Easy, Except When It Isn't - Barriers to Treatment Simplification, Alexander Thompson, St Vincents Hospital Melbourne, Australia

    14:20-14:40: Holistic, Yet Simple: Optimal Care for Persons Living with Hepatitis C Infection in the Modern DAA Era, Alexander Wong, University of Saskatchewan, Canada

    14:40-15:00: Questions/Panel Discussion

    15:00-15:15: Evaluation of Universal Hepatitis C Screening and Treatment Among Psychiatry Inpatients, Erin Mandel, University Health Network, Canada

    15:15-15:30: Lost to Follow Up in HCV: Can We Predict Who? Data from the BC-HCV Network, Alnoor Ramji, University of British Columbia, Canada

  • 15:15 15:30

    CanNASH: PM BREAK, Exhibits & Posters

  • 15:30 17:00

    CanHepC Session 4

    Health Services Research – Embracing the Digital Transformation of HCV Care

    Learning objectives:

    • Apply Lab resources and existing practices to optimise HCV diagnosis
    • Describe how multiple workers can be deployed to deliver HCV care
    • Explain the importance of relationality in innovative ECHO Hepatitis C care models
    • Summarize the value of incorporating Indigenous traditional wellness perspectives into Hepatitis C awareness resources

    Co-Chairs: Jason Altenberg, South Riverdale Community Health Centre, Canada & Anna-Maria Passos, McGill University, Canada

    CanHepC trainees introducing plenary speakers: Dahn Jeong and Gayatri Marathe

    15:30-15:50: Digitising HCV from the Flintstones to the Jetsons, John Dillon, University of Dundee, UK

    15:50-16:10: Alberta ECHO+: Innovation and Relationality Towards Improving Engagement for Hepatitis C Care with Indigenous Communities, Kate Dunn, Alberta Health Services, Canada

    16:10-16:30: Questions/Panel Discussion

    16:30-16:45: The Impact of New DAA Therapy on the Prevalence and Undiagnosed Proportion of Chronic Hepatitis C Infection in Ontario: A Model-Based Analysis, Farinaz Forouzannia, University of Waterloo, Canada

    16:45-17:00: Engagement with the HCV Care Ontario: A Population-Based Study, Aysegul Erman, Toronto General Hospital Research Institute, Canada

  • 15:30 17:00

    CanNASH Session 4

    Therapeutics

    Learning objectives:

    • Analyze the importance of sampling variability in the interpretation of trials in NASH
    • Evaluate the relative importance of liver and non-liver endpoints for persons with NASH
    • Review recent evidence regarding the role of nutrition and diet in NAFLD in terms of prevention and therapeutic strategies
    • Explain the latest nutritional recommendations for people with NAFLD

    Co-Moderators: Keyur Patel, University Health Network Toronto, Canada & Angela Crawley, University of Ottawa, Canada

    15:30-15:50: Natural History and Fibrosis Progression in Clinical Trials, Ian Rowe, University of Leeds, UK

    15:50-16:10: Nutrition and Diet in NAFLD: an Overview, Chantal Bémeur, CRCHUM - Université de Montréal, Canada

    16:10-16:30: Current and New Pharmacotherapy, Kris Kowdley

    16:30-16:50: The Role of A Gut Neuroimmune Circuit in NAFLD Development, Henry H. Nguyen, University of Calgary Cumming School of Medicine, Canada

    16:50-17:00: Q&A & Discussion

  • 17:00 17:20

    Awards & Closing Remarks

    17:00-17:10: CanHepC Trainee Awards Ceremony

    17:10-17:20: Closing Remarks, Nadine Kronfli, McGill University, Canada & Rodney Russell, Memorial University, Canada
  • 17:20 18:15

    Canadian Liver Meeting Opening

    Learning objectives:

    • Describe the importance of sex differences in cirrhosis prevalence and implications for prevention and treatment
    • Delineate the influence of chronic liver disease on reproductive health and vice versa

    17:20-17:30: Opening Remarks, Jordan Feld, University Health Network/TGH, Canada

    17:30-18:00: Gold Medal Lecture: introduced by Jennifer Flemming, Queen's University, Canada 

    Chronic Liver Disease Among Women: Disease Burden, Prevention and Treatment, Norah Terrault,University of Southern California, USA

    18:00-18:15: CASL Awards

  • 18:15 19:30

    CANHEPC, CanNASH, & CLM RECEPTION, Exhibits & CanHepC‑CanNASH POSTERS Tours

    1. Biomedical Poster Tour (18:15 start)

    Chair: Joyce Wilson

    18:15-18:25: Impact of Chronic HCV Infection on CD4 T-Cell Permissiveness to HIV Infection and Viral Reservoir Persistence, Samaa T. Gobran Poster No: P-035

    18:25-18:35: Investigating the Mechanism of NS5A-Mediated Viral Replication Organelle Biogenesis, Michelle Manolya Sag Poster No: P-034

    18:35-18:45: Hedgehog Signalling Mediates Interferon-Gamma Production, Supporting Gene Expression Signatures of Metabolic Dysfunction in Activated CD8+ T Cells in HCV Infection with Advanced Liver Fibrosis, Jeff Li Poster No: P-030

    Clinical Poster Tour (18:45 start)

    Chair: Alexandra King

    18:45-18:55: Leveraging COVID-19 Vaccination to Enhance HCV Testing in Priority Populations, Aaron Vanderhoff Poster No: P-01

    18:55-19:05: Impact of COVID-19 on Epic: Evaluation of Pharmacy-Based Identification and Treatment of Hepatitis C in Victoria, British Columbia, Chris Fraser Poster No: P-023

    19:05-19:15: Hepatic Decompensation and Hepatocellular Carcinoma After Stopping Nucleos(T)ide Analogue Therapy: Results from a Large, Global, Multi-Etchnic Cohort of Patients with Chronic Hepatitis B (Retract-B Study), Grishma Hirode Poster No: P-012

    19:15 – Poster Tour Completed

     

    2. Population Health Research Poster Tour (18:15 start)

    Chair: William Wong

    18:15-18:25: The Hepatitis C Care Cascade in Immigrant and Non-Immigrants in Quebec: a Population-Based Study, Ana Maria Passos-Castilho Poster No: P-040

    18:25-18:35: Validation of Case-Ascertainment Algorithms to Identify People Who Inject Drugs in Health Administrative Data in Ontario, Zoë Greenwald Poster No: P-067

    18:35-18:45: Chronic Pain, Substance Use, HCV and Other Related Harms in a Longitudinal Cohort of People who Inject Drugs in Montreal: Study Protocol, Sasha Udhesister Poster No: P-064

    Health Services Research Poster Tour (18:45 start)

    Chair: Mia Biondi

    18:45-18:55: Universal Hepatitis C Prenatal Screening, Subsequent Testing, and Linkage to Care at a Tertiary Care Centre in Ontario, Mia Biondi Poster: No P059

    18:55-19:05: Determining the Barriers and Enablers to Hepatitis C Antibody Screening and RNA Testing in Needle Syringe Programs: Preliminary Findings of the Hepcast Theory-Informed Qualitative Study with People who Inject Drugs, Guillaume Fontaine Poster No : P-050

    19:05-19:15: Gender, Incarceration and Cocaine Use: Barriers to HCV Treatment Uptake Persist for People Who Inject Drugs Despite Universal Coverage of Direct-Acting Antiviral Agents, Nathalie Jiang Poster No: P-062

    19:15 – Poster Tour Completed